Ultimovacs ASA
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.
Ultimovacs ASA (ULTI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: -0.299x
Based on the latest financial reports, Ultimovacs ASA (ULTI) has a cash flow conversion efficiency ratio of -0.299x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-24.70 Million) by net assets (Nkr82.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ultimovacs ASA - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Ultimovacs ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Ultimovacs ASA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ultimovacs ASA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alphageo (India) Limited
NSE:ALPHAGEO
|
0.038x |
|
NORTHROP GRUMMAN - Dusseldorf Stock Exchang
DU:NTH
|
0.074x |
|
Churchill Resources Inc.
PINK:CRICF
|
-0.124x |
|
MITSUI FUDOSAN LOG.PARK
F:85L
|
N/A |
|
Global Power Solutions Corp.
V:PWER
|
-1.154x |
|
S&S Healthcare Holding Ltd.
TWO:4198
|
-0.067x |
|
Emmbi Industries Limited
NSE:EMMBI
|
0.023x |
|
Outback Goldfields Corp
OTCQB:OZBKF
|
-0.097x |
Annual Cash Flow Conversion Efficiency for Ultimovacs ASA (2016–2024)
The table below shows the annual cash flow conversion efficiency of Ultimovacs ASA from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Nkr82.67 Million | Nkr-163.40 Million | -1.977x | -190.92% |
| 2023-12-31 | Nkr279.39 Million | Nkr-189.83 Million | -0.679x | -82.06% |
| 2022-12-31 | Nkr449.35 Million | Nkr-167.69 Million | -0.373x | -75.92% |
| 2021-12-31 | Nkr593.15 Million | Nkr-125.83 Million | -0.212x | +4.27% |
| 2020-12-31 | Nkr488.38 Million | Nkr-108.22 Million | -0.222x | -56.42% |
| 2019-12-31 | Nkr444.63 Million | Nkr-62.99 Million | -0.142x | +55.04% |
| 2018-12-31 | Nkr159.90 Million | Nkr-50.39 Million | -0.315x | -92.70% |
| 2017-12-31 | Nkr166.48 Million | Nkr-27.23 Million | -0.164x | +60.13% |
| 2016-12-31 | Nkr75.82 Million | Nkr-31.10 Million | -0.410x | -- |